Dr. Reddy's Laboratories
DRREDDY · NSE · Pharma · India
Financials at a glance
Source: Yahoo FinanceAnnual
Quarterly · last 5
Revenue (FY2026)
₹33,593 Cr
Net margin
12.8%
Revenue CAGR (3y)
+10.8%
Profit CAGR (3y)
-1.7%
Net profit (FY2026)
₹4,285 Cr
Ask MarketChacha about DRREDDY
Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.
Why it moved
- Sep 17, 2026
Gained as the Nifty Pharma index rose about 1.7% and investors rotated into defensive sectors during a flat, range-bound session. Dr Reddy's closed at around Rs 1,175 with no company-specific announcement reported.
- Aug 11, 2026
Dr Reddy's led NSE gainers as pharma was the top-performing sector, with investors rotating into defensive counters amid a weak, risk-off session tied to elevated crude oil and fading US-Iran deal hopes. No company-specific announcement was reported for the move.
- Jul 9, 2026
Dr Reddy's shares fell ~6% after the company delayed commercial supplies of its semaglutide product due to a quality issue with the active pharmaceutical ingredient (API) in certain batches.
source 1 ↗· confidence: high
Daily moves with the verified reason behind them. Education only — not investment advice.
On MarketChacha
Posts about DRREDDYFinancials
Yearly
| Period | Revenue | Net profit | Net margin |
|---|---|---|---|
| FY2026 | ₹33,593 Cr | ₹4,285 Cr | 12.8% |
| FY2025 | ₹32,554 Cr | ₹5,654 Cr | 17.4% |
| FY2024 | ₹27,916 Cr | ₹5,578 Cr | 20.0% |
| FY2023 | ₹24,670 Cr | ₹4,507 Cr | 18.3% |
Quarterly
| Period | Revenue | Net profit | Net margin |
|---|---|---|---|
| Q1 FY27 | ₹8,071 Cr | ₹444 Cr | 5.5% |
| Q4 FY26 | ₹7,516 Cr | ₹220 Cr | 2.9% |
| Q3 FY26 | ₹8,727 Cr | ₹1,210 Cr | 13.9% |
| Q2 FY26 | ₹8,805 Cr | ₹1,437 Cr | 16.3% |
| Q1 FY26 | ₹8,545 Cr | ₹1,418 Cr | 16.6% |
Figures as reported, in ₹ (crore). Source: Yahoo Finance.
Filings & announcements
2026
Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
BSE9/18/2026Clarification- Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
BSE9/18/2026Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
BSE9/11/2026Allotment of Employee Stock options
BSE9/10/2026Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
BSE8/14/2026Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
BSE8/14/2026Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2105
BSE8/7/2026Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2105
BSE8/7/2026Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
BSE8/7/2026Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015- Press Release
BSE8/1/2026Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
BSE7/29/2026Clarification- Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
BSE7/29/2026Dr Reddys Laboratories Ltd - 500124 - Clarification sought from Dr Reddys Laboratories Ltd
The Exchange has sought clarification from Dr Reddys Laboratories Ltd with reference to the media report appearing on https://www.business-standard.com dated July 28, 2026, (Link:https://www.business-standard.com/companies/news/dr-reddys-first-in-class-gonorrhoea-drug-gets-thailand-approval-after-us-nod-126072700632_1.html) ....
BSE7/28/2026materialDr Reddys Laboratories Ltd - 500124 - Announcement under Regulation 30 (LODR)-Change in Management
Disclosure under Regulation 30 of SEBI (LODR) Regulation, 2015
BSE7/23/2026Dr Reddys Laboratories Ltd - 500124 - Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Scrutinizer''s Report
BSE7/23/2026materialDr Reddys Laboratories Ltd - 500124 - Shareholder Meeting / Postal Ballot-Outcome of AGM
Outcome of 42nd Annual General Meeting
BSE7/23/2026materialDisclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
BSE7/9/2026Please find enclosed letter to shareholder in relation to Integrated Annual Report of the Company for FY 2025-26
BSE6/30/2026Dr Reddys Laboratories Ltd - 500124 - Business Responsibility and Sustainability Reporting (BRSR)
Please find enclosed Business Responsibility and Sustainability Report FY 2026
BSE6/30/2026Please find enclosed Notice of the 42nd Annual General Meeting of the Company.
BSE6/30/2026materialDr Reddys Laboratories Ltd - 500124 - Reg. 34 (1) Annual Report.
Please find enclosed Integrated Annual Report FY 2025-26
BSE6/30/2026Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
BSE6/25/2026Dr Reddys Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/07/2026 ,inter alia, to consider and approve the Un-audited Standalone ....
BSE6/22/2026material
In the news
- Dr. Reddy's Laboratories - Concurrent Gainers: 8 stocks that gain for 5 days in a rowThe Economic Times · 10/31/2026
- Pomerantz LLP investigates Dr. Reddy's over semaglutide-linked lossesscanx.trade · 10/29/2026
- Dr. Reddy’s Files SEC Form 6-K and Publishes Q2 FY27 Earnings Call TranscriptTipRanks · 10/29/2026
- Stocks to Watch Today: Dr Reddys Labs, Fortis Healthcare, Titagarh Rail, Hero MotoCorp, RR Kabel, Meesho,...Moneycontrol.com · 10/29/2026
- Dr. Reddy's Laboratories - Positive Breakout: These 8 stocks cross above their 200 DMAsThe Economic Times · 10/27/2026
- Dr. Reddy's Laboratories Limited (DRREDDY) share price — eduinvestingHowl.Link · 10/27/2026
- Five Stocks To Buy Today, October 27: Dr Reddy's Laboratories, Asahi India Glass, Ajanta Pharma, And MoreNDTV Profit · 10/26/2026
- Dr. Reddy's Laboratories Ltd Stock 12‑Month Price Target Raised to $14.01, Implies 6% UpsideTradingView · 10/26/2026
Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.